

**Bispecific Antibodies Market (5th Edition):
Distribution by Therapeutic Area (Autoimmune
Disorders, Genetic Disorders, Hematological
Malignancies, Ophthalmic Disorders, Skin Cancers
And Solid Tumors), Mechanism of Action (Cytokines
Retargeting / Neutralization, Dual Ligands Blocking,
Resistance Factors Co-Targeting, Targeting Tumor
Angiogenesis, T-Cell Retargeting / Activation and
Others), Target Antigen (C5-Albumin, CD20 x CD3,
CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x
CD3, Factor IXa x Factor X, gp100 x CD3, HER2 x
HER2, PD-1 x CTLA-4, PD-L1 x TGF?, TNF-? x HAS,
VEGF x DLL4 and VEGF-A x ANG2), Antibody Format
(Asymmetric And Fragments), Key Players (Akeso
Biopharma, Alexion, Amgen, Genmab, Immunocore,
Janssen Research & Development, Linton Pharm,
Merck, OncXerna Therapeutics, Pfizer, Roche, Taisho
Pharmaceutical and Zymeworks) and Key
Geographical Regions (North America, Europe, Asia
and Rest of the World): Industry Trends and Global
Forecasts, 2023-2035**

<https://marketpublishers.com/r/B145644A487BEN.html>

Date: May 2023

Pages: 391

Price: US\$ 4,799.00 (Single User License)

ID: B145644A487BEN

Abstracts

The bispecific antibodies market is expected to reach USD 5.6 billion by 2023 and is anticipated to grow at a CAGR of 9.5% during the forecast period 2023-2035

Bispecific antibodies (BsAbs) represent an increasingly prominent category of immunotherapeutic agents adept at simultaneously engaging two distinct antigens or discrete epitopes on the same antigen. These biologics function by activating immune effector cells to effectively combat cancerous cells through various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Importantly, bispecific antibody drugs showcase unique biological and pharmacological characteristics, available in a diverse range of formats, promising significant potential for therapeutic applications.

As of recent approvals, regulatory authorities have granted authorization for nine bispecific antibodies for therapeutic use, listed chronologically by their most recent endorsements: Tecvayli™ (October 2022), Nanozora® (September 2022), AK104 (June 2022), Lunsumio® (June 2022), VABYSMO™ (February 2022), KIMMTRAK® (January 2022), RYBREVANT™ (May 2021), Hemlibra® (November 2017), and Blincyto® (December 2014). Furthermore, a notable surge in clinical trials investigating bispecific antibodies has emerged in recent years, driven by increasing favor and recognized therapeutic potential for such candidates. It is foreseeable that as more of these therapeutic contenders advance into clinical stages or gain regulatory endorsement, the market for bispecific antibody therapeutics is positioned for robust expansion and sustained growth.

Report Coverage

The report conducts an analysis of the bispecific antibodies market, focusing on various aspects such as therapeutic area, mechanism of action, target antigen, antibody format, key players, and geographical regions.

It evaluates factors influencing market growth, including drivers, restraints, opportunities, and challenges.

The report appraises the potential advantages and hurdles in the market, providing insights into the competitive landscape for leading market players.

Forecasts are made regarding revenue for market segments across four major regions.

An in-depth examination of the bispecific antibodies market landscape is presented, encompassing approved, in-development, and preclinical stage antibodies. The report explores historical context, structural variations, mechanisms of action, and diverse applications of bispecific antibodies. It encompasses an analysis of over 220 existing antibodies and 180 in preclinical stages, considering developer details, developmental stages, target antigens, and therapeutic applications.

It outlines current market trends through graphical representations, illustrating development phases, disease segments, and headquarters' locations of these antibodies. Additionally, it evaluates more than 80 technology platforms used for bispecific antibody production, offering a comparative analysis based on development strength, company experience, size, and location.

The report explores major pharmaceutical players in this sector, utilizing analyses like spider web and heat maps to assess competition, clinical trials, partnerships, and technology portfolios. Detailed profiles of key developers highlight their backgrounds, executive teams, financial information, drug portfolios, recent developments, and future prospects.

Furthermore, it investigates partnerships within the domain, scrutinizing parameters such as partnership types, disease segments, payment models, deal amounts, and active players. It discusses challenges and considerations in the manufacturing process of bispecific antibodies, along with a list of pertinent contract manufacturing and research organizations.

A comprehensive overview of ongoing and planned studies, regulatory guidelines by prominent agencies, and promotional strategies for approved antibodies like Blincyto® and Hemlibra® is provided. Finally, a market forecast analysis until 2035 presents sales projections based on therapeutic areas, mechanisms of action, target antigens, antibody formats, key players, and geographical regions.

Summarizing industry trends, market drivers, and challenges within a SWOT framework provides a qualitative analysis using Harvey ball representations to delineate the relative impact of these parameters on the overall market.

Key Market Companies

Akeso Biopharma

Alexion

Amgen

Genmab

Immunocore

Janssen Research & Development

Linton Pharm

Merck

OncXerna Therapeutics

Pfizer

Roche

Taisho Pharmaceutical

Zymeworks

Contents

1. PREFACE

- 1.1. Introduction
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Frequently Asked Questions
- 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Introduction to Antibodies
 - 3.2.1. Structure
 - 3.2.2. Functions
 - 3.2.3. Mechanism of Action
- 3.3. Antibody Therapeutics
 - 3.3.1. Historical Evolution of Antibody Therapeutics
 - 3.3.2. Key Approved Antibody Therapeutics
 - 3.3.3. Advanced Antibody Therapeutics
 - 3.3.3.1. Fc Engineered and Glycoengineered Antibodies
 - 3.3.3.2. Antibody Fragments
 - 3.3.3.3. Fusion Proteins
 - 3.3.3.4. Intrabodies
 - 3.3.3.5. Bispecific Antibodies
- 3.4. Bispecific Antibody Formats
 - 3.4.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
 - 3.4.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
 - 3.4.1.2. Bispecific Single-Domain Antibody Fusion Proteins
 - 3.4.1.3. Diabodies / Diabody Derivatives
 - 3.4.1.4. Fusion Proteins
 - 3.4.1.5. Fusion Proteins Devoid of Fc Regions
 - 3.4.2. Immunoglobulin G Based Formats (Fc Dependent Antibody Formats)
 - 3.4.2.1. Quadromas
 - 3.4.2.2. Knobs-Into-Holes

- 3.4.2.3. Dual Variable Domain Ig
- 3.4.2.4. IgG-scFv
- 3.4.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
- 3.4.2.6. Half Molecule Exchange
- 3.4.2.7. ??- Bodies
- 3.5. Mechanism of Action of Bispecific Antibody Therapeutics
 - 3.5.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
 - 3.5.2. Directly Targeting Malignant / Tumor Cells
 - 3.5.3. Retargeting of Toxins
 - 3.5.4. Targeting Tumor Angiogenesis
 - 3.5.5. Other Mechanisms
- 3.6. Applications of Bispecific Antibodies

4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES

- 4.1. Chapter Overview
- 4.2. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
 - 4.2.1. Analysis by Phase of Development
 - 4.2.2. Analysis by Target Antigen
 - 4.2.3. Analysis by Type of Therapy
 - 4.2.4. Analysis by Route of Administration
 - 4.2.5. Analysis by Method of Administration
 - 4.2.6. Analysis by Target Indication
 - 4.2.7. Analysis by Therapeutic Area
 - 4.2.8. Analysis by Disease Segment
- 4.3. Approved and Clinical Bispecific Antibody Therapeutics: Overall Developer Landscape
 - 4.3.1. Analysis by Year of Establishment
 - 4.3.2. Analysis by Company Size
 - 4.3.3. Analysis by Location of Headquarters

5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES

- 5.1. Chapter Overview
- 5.2. Preclinical Bispecific Antibody Therapeutics: Overall Market Landscape
 - 5.2.1. Analysis by Stage of Development
 - 5.2.2. Analysis by Target Antigen
 - 5.2.3. Analysis by Disease Segment
- 5.3. Preclinical Bispecific Antibody Therapeutics: Overall Developer Landscape

- 5.3.1. Analysis by Year of Establishment
- 5.3.2. Analysis by Company Size
- 5.3.3. Analysis by Location of Headquarters

6. KEY INSIGHTS

- 6.1. Chapter Overview
- 6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
 - 6.2.1. Analysis by Phase of Development and Route of Administration
 - 6.2.2. Analysis by Phase of Development and Disease Segment
 - 6.2.3. Analysis by Phase of Development and Location of Developer's Headquarters
- 6.3. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
 - 6.3.1. Analysis by Stage of Development and Therapeutic Area
 - 6.3.2. Analysis by Stage of Development and Location of Developer Headquarters
- 6.4. Bispecific Antibody Therapeutics Developers Landscape: Key Insights
 - 6.4.1. Distribution by Stage of Development
 - 6.4.2. Distribution by Stage of Development and Region of Developer Headquarters

7. TECHNOLOGY ASSESSMENT FRAMEWORK

- 7.1. Chapter Overview
- 7.2. Bispecific Antibody Therapeutics: List of Technology Platforms
- 7.3. Bispecific Antibody Technology Platforms: Comparative Analysis
 - 7.3.1. Analysis by Technologies for Approved and Clinical Drugs
 - 7.3.2. Analysis by Technologies for Preclinical Drugs
- 7.4. Most Popular Technology Platforms: Analysis by Stage of Development
- 7.5. Bispecific Antibody Technology Platform Developers: Analysis by Location of Headquarters

8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS

- 8.1. Chapter Overview
- 8.2. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
- 8.3. Big Pharma Players: Comparative Clinical Pipeline Analysis
 - 8.3.1. Analysis by Target Antigen
 - 8.3.2. Analysis by Antibody Format
 - 8.3.3. Analysis by Mechanism of Action
 - 8.3.4. Analysis by Therapeutic Area

9. COMPANY PROFILES

9.1. Chapter Overview

9.2. Akeso Biopharma

9.2.1. Company Overview

9.2.2. Financial Performance

9.2.3. Drug Portfolio

9.2.4. Recent Developments and Future Outlook

9.3. Alphamab Oncology

9.3.1. Company Overview

9.3.2. Financial Performance

9.3.3. Drug Portfolio

9.3.4. Recent Developments and Future Outlook

9.4. Amgen

9.4.1. Company Overview

9.4.2. Financial Performance

9.4.3. Drug Portfolio

9.4.4. Recent Developments and Future Outlook

9.5. Merck

9.5.1. Company Overview

9.5.2. Financial Performance

9.5.3. Drug Portfolio

9.5.4. Recent Developments and Future Outlook

9.6. Regeneron

9.6.1. Company Overview

9.6.2. Financial Performance

9.6.3. Drug Portfolio

9.6.4. Recent Developments and Future Outlook

9.7. Roche

9.7.1. Company Overview

9.7.2. Financial Performance

9.7.3. Drug Portfolio

9.7.4. Recent Developments and Future Outlook

9.8. Xencor

9.8.1. Company Overview

9.8.2. Financial Performance

9.8.3. Drug Portfolio

9.8.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations

10.3.1. Analysis by Year of Partnership

10.3.2. Analysis by Type of Partnership

10.3.3. Analysis by Year and Type of Partnership

10.3.4. Analysis by Disease Segment

10.3.5. Analysis by Type of Payment Model Employed and Deal Amount

10.3.6. Analysis by Year of Agreement, Type of Payment Model Employed and Deal Amount

10.3.7. Analysis by Disease Segment, Type of Payment Model Employed and Deal Amount

10.3.8. Most Active Players: Analysis by Number of Partnership Instances

10.3.9. Most Popular Technologies: Analysis by Number of Partnership Instances

10.3.10. Analysis by Region

10.3.11. Intercontinental and Intracontinental Agreements

11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS

11.1. Chapter Overview

11.2. Manufacturing of Bispecific Antibody Therapeutics

11.2.1. Key Considerations for Manufacturing and Associated Challenges

11.2.2. Contract Manufacturing Organizations (CMOs)

11.2.2.1. Bispecific Antibody Therapeutics: List of CMOs

11.2.3. Contract Research Organizations (CROs)

11.2.3.1. Bispecific Antibody Therapeutics: List of CROs

11.3. Key Considerations for Selecting a Suitable CMO / CRO Partner

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis

12.3.1. Analysis by Trial Registration Year

12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year

12.3.3. Analysis by Trial Phase

- 12.3.4. Analysis of Enrolled Patient Population by Trial Phase
- 12.3.5. Analysis by Trial Recruitment Status
- 12.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
- 12.3.7. Analysis by Type of Study
- 12.3.8. Analysis by Study Design
- 12.3.9. Analysis by Type of Sponsor / Collaborator
- 12.3.10. Leading Industry Players: Analysis by Number of Registered Trials
- 12.3.11. Leading Non-Industry Players: Analysis by Number of Registered Trials
- 12.3.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
- 12.3.13. Analysis by Geography
- 12.3.14. Analysis by Trial Recruitment Status and Geography
- 12.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES

- 13.1. Chapter Overview
- 13.2. Guidelines Issued by Regulatory Authorities
 - 13.2.1. US Food and Drug Administration (FDA)
 - 13.2.1.1. Pharma Companies' Response to the FDA Draft Guidance
 - 13.2.2. World Health Organization (WHO)

14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

- 14.1. Chapter Overview
- 14.2. Key Channels Used for Promotional Campaigns
 - 14.2.1. Product Websites
 - 14.2.2. Patient Assistance Programs
 - 14.2.3. Participation in Conferences
 - 14.2.4. Collaboration with Stakeholders
 - 14.2.5. Drug Approval Across Multiple Geographies
- 14.3. Other Channels Used for Promotional and Marketing Strategies
- 14.4. Summary: Promotional and Marketing Strategy Leveraged by Bispecific Antibody Developers
- 14.5. Promotional Analysis: Blincyto®
 - 14.5.1. Drug Overview
 - 14.5.2. Product Website analysis
 - 14.5.2.1. Messages for Healthcare Professionals
 - 14.5.2.1.1. For MRD Positive B cell precursor ALL

- 14.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
- 14.5.2.2. Messages for Patients
- 14.5.3. Patient Support Services and Informative Downloads
- 14.5.4. Other Promotional Strategies
 - 14.5.4.1. Presence in Conferences
- 14.6. Promotional Analysis: Hemlibra®
 - 14.6.1. Drug Overview
 - 14.6.2. Product Website Analysis
 - 14.6.2.1. Messages for Healthcare Professionals
 - 14.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
 - 14.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
 - 14.6.2.3. Messages for Patients
 - 14.6.3. Patient Support Services and Informative Downloads
 - 14.6.3.1. Co-pay Program
 - 14.6.3.2. Independent Co-pay Assistance Foundation
 - 14.6.3.3. Genentech Patient Foundation
 - 14.6.4. Other Promotional Strategies
 - 14.6.4.1. Presence in Conferences

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

- 15.1. Chapter Overview
- 15.2. Scope and Limitations
- 15.3. Forecast Methodology and Key Assumptions
- 15.4. Global Bispecific Antibody Therapeutics Market, 2023-2035
 - 15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
 - 15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action, 2023 and 2035
 - 15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen, 2023 and 2035
 - 15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format, 2023 and 2035
 - 15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players, 2023 and 2035
 - 15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography, 2023 and 2035
- 15.5. Bispecific Antibody Market: Value Creation Analysis
- 15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts

- 15.6.1. AK104 (Akeso Biopharma)
 - 15.6.1.1. Target Patient Population
 - 15.6.1.2. Sales Forecast
 - 15.6.1.3. Net Present Value
 - 15.6.1.4. Value Creation Analysis
- 15.6.2. Blincyto™ (Amgen)
 - 15.6.2.1. Target Patient Population
 - 15.6.2.2. Sales Forecast
 - 15.6.2.3. Net Present Value
 - 15.6.2.4. Value Creation Analysis
- 15.6.3. Hemlibra® (Roche)
 - 15.6.3.1. Target Patient Population
 - 15.6.3.2. Sales Forecast
 - 15.6.3.3. Net Present Value
 - 15.6.3.4. Value Creation Analysis
- 15.6.4. Kimmtrak® (Immunocore)
 - 15.6.4.1. Target Patient Population
 - 15.6.4.2. Sales Forecast
 - 15.6.4.3. Net Present Value
 - 15.6.4.4. Value Creation Analysis
- 15.6.5. Lunsumio® (Roche)
 - 15.6.5.1. Target Patient Population
 - 15.6.5.2. Sales Forecast
 - 15.6.5.3. Net Present Value
 - 15.6.5.4. Value Creation Analysis
- 15.6.6. Nanozora® (Taisho Pharmaceutical)
 - 15.6.6.1. Target Patient Population
 - 15.6.6.2. Sales Forecast
 - 15.6.6.3. Net Present Value
 - 15.6.6.4. Value Creation Analysis
- 15.6.7. Rybrevant™ (Janssen Research & Development)
 - 15.6.7.1. Target patient Population
 - 15.6.7.2. Sales Forecast
 - 15.6.7.3. Net Present Value
 - 15.6.7.4. Value Creation Analysis
- 15.6.8. Tecvayli™ (Janssen Research & Development)
 - 15.6.8.1. Target Patient Population
 - 15.6.8.2. Sales Forecast
 - 15.6.8.3. Net Present Value

- 15.6.8.4. Value Creation Analysis
- 15.6.9. Vabysmo™ (Roche)
 - 15.6.9.1. Target Patient Population
 - 15.6.9.2. Sales Forecast
 - 15.6.9.3. Net Present Value
 - 15.6.9.4. Value Creation Analysis
- 15.6.10. AK112 (Akeso Biopharma)
 - 15.6.10.1. Target Patient Population
 - 15.6.10.2. Sales Forecast
 - 15.6.10.3. Net Present Value
 - 15.6.10.4. Value Creation Analysis
- 15.6.11. ALXN1720 (Alexion)
 - 15.6.11.1. Target Patient Population
 - 15.6.11.2. Sales Forecast
 - 15.6.11.3. Net Present Value
 - 15.6.11.4. Value Creation Analysis
- 15.6.12. GEN3013 (Genmab)
 - 15.6.12.1. Target Patient Population
 - 15.6.12.2. Sales Forecast
 - 15.6.12.3. Net Present Value
 - 15.6.12.4. Value Creation Analysis
- 15.6.13. Glofitamab (Roche)
 - 15.6.13.1. Target Patient Population
 - 15.6.13.2. Sales Forecast
 - 15.6.13.3. Net Present Value
 - 15.6.13.4. Value Creation Analysis
- 15.6.14. LP000 (Linton Pharm)
 - 15.6.14.1. Target Patient Population
 - 15.6.14.2. Sales Forecast
 - 15.6.14.3. Net Present Value
 - 15.6.14.4. Value Creation Analysis
- 15.6.15. M7824 (Merck)
 - 15.6.15.1. Target Patient Population
 - 15.6.15.2. Sales Forecast
 - 15.6.15.3. Net Present Value
 - 15.6.15.4. Value Creation Analysis
- 15.6.16. OMP 305B83 (Mereo BioPharma)
 - 15.6.16.1. Target Patient Population
 - 15.6.16.2. Sales Forecast

- 15.6.16.3. Net Present Value
- 15.6.16.4. Value Creation Analysis
- 15.6.17. PF-06863135 (Pfizer)
 - 15.6.17.1. Target Patient Population
 - 15.6.17.2. Sales Forecast
 - 15.6.17.3. Net Present Value
 - 15.6.17.4. Value Creation Analysis
- 15.6.18. ZW25 (Zymeworks)
 - 15.6.18.1. Target Patient Population
 - 15.6.18.2. Sales Forecast
 - 15.6.18.3. Net Present Value
 - 15.6.18.4. Value Creation Analysis
- 15.7. Concluding Remarks

16. SWOT ANALYSIS

- 16.1. Chapter Overview
- 16.2. Strengths
 - 16.2.1. Enhanced Specificity
 - 16.2.2. Diverse Application Areas
 - 16.2.3. Lower Drug Resistance
 - 16.2.4. Success of Approved Products
- 16.3. Weaknesses
 - 16.3.1. Uncertainties with Safety of Therapeutic Candidates
 - 16.3.2. Complex Purification and Downstream Processing
 - 16.3.3. Dimerization in Antibodies with Fc-region
- 16.4. Opportunities
 - 16.4.1. Life Cycle Management of Novel Therapies
 - 16.4.2. Growing Number of High Value Partnerships
 - 16.4.3. Expertise Available with Contract Manufacturing Organizations
 - 16.4.4. Emergence of Advanced Technologies
- 16.5. Threats
 - 16.5.1. Rise in Attrition Rate of Clinical Stage Candidates
- 16.6. Concluding Remarks

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

- 18.1. Chapter Overview
- 18.2. CytomX Therapeutics
 - 18.2.1. Company Snapshot
 - 18.2.2. Interview Transcript
- 18.3. F-star
 - 18.3.1. Company Snapshot
 - 18.3.2. Interview Transcript
- 18.4. Immunai
 - 18.4.1. Company Snapshot
 - 18.4.2. Interview Transcript
- 18.5. Innovent Biologics
 - 18.5.1. Company Snapshot
 - 18.5.2. Interview Transcript
- 18.6. SYNIMMUNE
 - 18.6.1. Company Snapshot
 - 18.6.2. Interview Transcript
- 18.7. University of Freiburg
 - 18.7.1. Company Snapshot
 - 18.7.2. Interview Transcript

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

I would like to order

Product name: Bispecific Antibodies Market (5th Edition): Distribution by Therapeutic Area (Autoimmune Disorders, Genetic Disorders, Hematological Malignancies, Ophthalmic Disorders, Skin Cancers And Solid Tumors), Mechanism of Action (Cytokines Retargeting / Neutralization, Dual Ligands Blocking, Resistance Factors Co-Targeting, Targeting Tumor Angiogenesis, T-Cell Retargeting / Activation and Others), Target Antigen (C5-Albumin, CD20 x CD3, CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x CD3, Factor IXa x Factor X, gp100 x CD3, HER2 x HER2, PD-1 x CTLA-4, PD-L1 x TGF?, TNF-? x HAS, VEGF x DLL4 and VEGF-A x ANG2), Antibody Format (Asymmetric And Fragments), Key Players (Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Janssen Research & Development, Linton Pharm, Merck, OncXerna Therapeutics, Pfizer, Roche, Taisho Pharmaceutical and Zymeworks) and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/B145644A487BEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B145644A487BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970